{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:04:38Z","timestamp":1719187478822},"reference-count":131,"publisher":"Informa UK Limited","issue":"23","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.2217\/fon-2017-0224","type":"journal-article","created":{"date-parts":[[2017,10,6]],"date-time":"2017-10-06T13:44:19Z","timestamp":1507297459000},"page":"2083-2101","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Advances in systemic therapy for malignant mesothelioma: future perspectives"],"prefix":"10.1080","volume":"13","author":[{"given":"Navid","family":"Sobhani","sequence":"first","affiliation":[{"name":"Department of Medical,Surgical,&amp; Health Sciences,University of Trieste,\rPiazza Ospitale 1 34129 Trieste,\rItaly"},{"name":"Department of Medical,Surgical, &amp; Health Sciences,Teaching Hospital of Cattinara,University of Trieste,\rVia Fiume 447,\r34129 Trieste,\rItaly"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia Paola","family":"Corona","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology,Peter MacCallum Cancer Center,\rMoorabbin Campus,\r823\u2013865 Centre Rd,\rBentleigh East VIC 3165,\rAustralia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Bonazza","sequence":"additional","affiliation":[{"name":"Department of Medical,Surgical, &amp; Health Sciences,Teaching Hospital of Cattinara,University of Trieste,\rVia Fiume 447,\r34129 Trieste,\rItaly"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Ianza","sequence":"additional","affiliation":[{"name":"Department of Medical,Surgical,&amp; Health Sciences,University of Trieste,\rPiazza Ospitale 1 34129 Trieste,\rItaly"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tania","family":"Pivetta","sequence":"additional","affiliation":[{"name":"Department of Medical,Surgical, &amp; Health Sciences,Teaching Hospital of Cattinara,University of Trieste,\rVia Fiume 447,\r34129 Trieste,\rItaly"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giandomenico","family":"Roviello","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit,Department of Oncology,San Donato Hospital,\rArezzo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Cortale","sequence":"additional","affiliation":[{"name":"Department of Medical,Surgical, &amp; Health Sciences,Teaching Hospital of Cattinara,University of Trieste,\rVia Fiume 447,\r34129 Trieste,\rItaly"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Guglielmi","sequence":"additional","affiliation":[{"name":"Department of Medical,Surgical,&amp; Health Sciences,University of Trieste,\rPiazza Ospitale 1 34129 Trieste,\rItaly"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Zanconati","sequence":"additional","affiliation":[{"name":"Department of Medical,Surgical, &amp; Health Sciences,Teaching Hospital of Cattinara,University of Trieste,\rVia Fiume 447,\r34129 Trieste,\rItaly"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Generali","sequence":"additional","affiliation":[{"name":"Department of Medical,Surgical,&amp; Health Sciences,University of Trieste,\rPiazza Ospitale 1 34129 Trieste,\rItaly"},{"name":"Breast Cancer Unit,ASST Cremona,\rViale Concordia 1,\r26100,\rCremona,\rItaly"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2017,10,6]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12199-007-0017-6"},{"issue":"4","key":"e_1_3_2_3_1","first-page":"491","article-title":"Malignant pleural mesothelioma: an epidemiological perspective","volume":"1","author":"Robinson BM","year":"2012","unstructured":"Robinson BM . Malignant pleural mesothelioma: an epidemiological perspective. Ann. Cardiothorac. Surg.1(4), 491\u2013496 (2012).","journal-title":"Ann. Cardiothorac. Surg."},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-publhealth-031811-124704"},{"issue":"4","key":"e_1_3_2_5_1","first-page":"260","article-title":"Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province","volume":"17","author":"Wagner JC","year":"1960","unstructured":"Wagner JC , SleggsCA, MarchandP. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br. J. Ind. Med.17(4), 260\u2013271 (1960).","journal-title":"Br. J. Ind. Med."},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1183\/20734735.001011"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(03)00087-1"},{"issue":"5","key":"e_1_3_2_8_1","first-page":"1524","article-title":"SV40 induces mesotheliomas in hamsters","volume":"142","author":"Cicala C","year":"1993","unstructured":"Cicala C , PompettiF, CarboneM. SV40 induces mesotheliomas in hamsters. Am. J. Pathol.142(5), 1524\u20131533 (1993).","journal-title":"Am. J. Pathol."},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.170207097"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.912"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67025-0"},{"issue":"30","key":"e_1_3_2_12_1","first-page":"237","article-title":"Asbestos retention in human respiratory tissues: comparative measurements in lung parenchyma and in parietal pleura","author":"Sebastien P","year":"1980","unstructured":"Sebastien P , JansonX, GaudichetA, HirschA, BignonJ. Asbestos retention in human respiratory tissues: comparative measurements in lung parenchyma and in parietal pleura. IARC Sci. Publ. (30), 237\u2013246 (1980).","journal-title":"IARC Sci. Publ."},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0232-1513(87)80044-0"},{"issue":"4","key":"e_1_3_2_14_1","first-page":"792","article-title":"Behavior of crocidolite asbestos during mitosis in living vertebrate lung epithelial cells","volume":"55","author":"Ault JG","year":"1995","unstructured":"Ault JG , ColeRW, JensenCG, JensenLC, BachertLA, RiederCL. Behavior of crocidolite asbestos during mitosis in living vertebrate lung epithelial cells. Cancer Res.55(4), 792\u2013798 (1995).","journal-title":"Cancer Res."},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0013-9351(87)80090-7"},{"issue":"3","key":"e_1_3_2_16_1","first-page":"L471","article-title":"Asbestos causes DNA strand breaks in cultured pulmonary epithelial cells: role of iron-catalyzed free radicals","volume":"268","author":"Kamp DW","year":"1995","unstructured":"Kamp DW , IsrabianVA, PreusenSE, ZhangCX, WeitzmanSA. Asbestos causes DNA strand breaks in cultured pulmonary epithelial cells: role of iron-catalyzed free radicals. Am. J. Physiol.268(3 Pt 1), L471\u2013L480 (1995).","journal-title":"Am. J. Physiol."},{"issue":"23","key":"e_1_3_2_17_1","first-page":"5334","article-title":"Asbestos causes stimulation of the extracellular signal-regulated kinase 1 mitogen-activated protein kinase cascade after phosphorylation of the epidermal growth factor receptor","volume":"56","author":"Zanella CL","year":"1996","unstructured":"Zanella CL , PosadaJ, TrittonTR, MossmanBT. Asbestos causes stimulation of the extracellular signal-regulated kinase 1 mitogen-activated protein kinase cascade after phosphorylation of the epidermal growth factor receptor. Cancer Res.56(23), 5334\u20135338 (1996).","journal-title":"Cancer Res."},{"issue":"15","key":"e_1_3_2_18_1","first-page":"4169","article-title":"A mutant epidermal growth factor receptor targeted to lung epithelium inhibits asbestos-induced proliferation and proto-oncogene expression","volume":"62","author":"Manning CB","year":"2002","unstructured":"Manning CB , CumminsAB, JungMWet al. A mutant epidermal growth factor receptor targeted to lung epithelium inhibits asbestos-induced proliferation and proto-oncogene expression. Cancer Res.62(15), 4169\u20134175 (2002).","journal-title":"Cancer Res."},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.22724"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1159\/000109618"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-437X(99)80004-5"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2008.02.013"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0229"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13174"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-5002(02)00178-2"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0229"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2014.10.007"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.136"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20005.14.589"},{"key":"e_1_3_2_30_1","article-title":"Improving quality of life in patients with malignant pleural mesothelioma: results of the randomized pemetrexed + cisplatin vs cisplatin trial using the LCSS-meso instrument","volume":"22","author":"Gralla RJ","year":"2003","unstructured":"Gralla RJ , HollenPJ, LiepaAMet al. Improving quality of life in patients with malignant pleural mesothelioma: results of the randomized pemetrexed + cisplatin vs cisplatin trial using the LCSS-meso instrument. Proc. Am. Soc. Clin. Oncol.22, Abstract 2684 (2003).","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S1603"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31817c73d6"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.3190"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1519-z"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600118"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2007.09.018"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-013-1015-3"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2013.07.002"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.5869"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-014-2429-5"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11405"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910615)67:12<2984::AID-CNCR2820671208>3.0.CO;2-Q"},{"issue":"3","key":"e_1_3_2_43_1","first-page":"118","article-title":"Phase II study with the combination of cisplatin and doxorubicin in advanced malignant mesothelioma of the pleura","volume":"11","author":"Henss H","year":"1988","unstructured":"Henss H , FiebigHH, SchildgeJ, ArnoldH, HasseJ. Phase II study with the combination of cisplatin and doxorubicin in advanced malignant mesothelioma of the pleura. Onkologie11(3), 118\u2013120 (1988).","journal-title":"Onkologie"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2005.05.007"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1177\/030089160509100104"},{"issue":"9","key":"e_1_3_2_46_1","first-page":"857","article-title":"Phase II trial of mitomycin in malignant mesothelioma","volume":"71","author":"Bajorin D","year":"1987","unstructured":"Bajorin D , KelsenD, MintzerDM. Phase II trial of mitomycin in malignant mesothelioma. Cancer Treat. Rep.71(9), 857\u2013858 (1987).","journal-title":"Cancer Treat. Rep."},{"issue":"4","key":"e_1_3_2_47_1","first-page":"1688","article-title":"Experimental and clinical activity of mitomycin C and cis-diamminedichloroplatinum in malignant mesothelioma","volume":"44","author":"Chahinian AP","year":"1984","unstructured":"Chahinian AP , NortonL, HollandJF, SzrajerL, HartRD. Experimental and clinical activity of mitomycin C and cis-diamminedichloroplatinum in malignant mesothelioma. Cancer Res.44(4), 1688\u20131692 (1984).","journal-title":"Cancer Res."},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19970515)79:10<1897::AID-CNCR9>3.0.CO;2-D"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22366"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(92)90709-Q"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2013.118"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-5002(99)00030-6"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-5002(02)00536-6"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2013.11.011"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2008.04.001"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60727-8"},{"issue":"7","key":"e_1_3_2_57_1","first-page":"1983","article-title":"Molecular determinants of apoptosis induced by the cytotoxic ribonuclease onconase: evidence for cytotoxic mechanisms different from inhibition of protein synthesis","volume":"60","author":"Iordanov MS","year":"2000","unstructured":"Iordanov MS , RyabininaOP, WongJet al. Molecular determinants of apoptosis induced by the cytotoxic ribonuclease onconase: evidence for cytotoxic mechanisms different from inhibition of protein synthesis. Cancer Res.60(7), 1983\u20131994 (2000).","journal-title":"Cancer Res."},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.1.274"},{"key":"e_1_3_2_59_1","article-title":"Phase III randomized trial of onconase (ONC) versus doxorubicin (DOX) in patients (Pts) with unresectable malignant mesothelioma (UMM): analysis of survival","volume":"19","author":"Vogelzang N","year":"2000","unstructured":"Vogelzang N , TaubR, ShinD. Phase III randomized trial of onconase (ONC) versus doxorubicin (DOX) in patients (Pts) with unresectable malignant mesothelioma (UMM): analysis of survival. Proc. Am. Soc. Clin. Oncol.19, Abstract 2274 (2000).","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S2383"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-13-0926"},{"key":"e_1_3_2_62_1","first-page":"1","article-title":"The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the streptococcus erysipelas and the bacillus prodigiosus)","volume":"3","author":"Coley WB","year":"1910","unstructured":"Coley WB . The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the streptococcus erysipelas and the bacillus prodigiosus). Proc. R. Soc. Med.3(Surg Sect), 1\u201348 (1910).","journal-title":"Proc. R. Soc. Med."},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2005.11.005"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.4.3.1644"},{"issue":"26","key":"e_1_3_2_65_1","first-page":"1007","article-title":"Lymphocytic infiltration of pleural mesothelioma and its significance for survival","volume":"61","author":"Leigh RA","year":"1982","unstructured":"Leigh RA , WebsterI. Lymphocytic infiltration of pleural mesothelioma and its significance for survival. S. Afr. Med. J.61(26), 1007\u20131009 (1982).","journal-title":"S. Afr. Med. J."},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.7.1027"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121071"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000177"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901060"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1009285"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2007.10.026"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-010-0881-6"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-017-0975-5"},{"issue":"8","key":"e_1_3_2_74_1","first-page":"277","article-title":"Immunotherapy with BCG vaccine in 30 cases of mesothelioma","volume":"61","author":"Webster I","year":"1982","unstructured":"Webster I , CochraneJW, BurkhardtKR. Immunotherapy with BCG vaccine in 30 cases of mesothelioma. S. Afr. Med. J.61(8), 277\u2013278 (1982).","journal-title":"S. Afr. Med. J."},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.04.040186.003341"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0062"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.4161\/cam.4.1.11361"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70381-4"},{"key":"e_1_3_2_79_1","article-title":"Tremelimumab misses OS endpoint in Phase IIb mesothelioma trial","author":"Inman S","year":"2016","unstructured":"Inman S . Tremelimumab misses OS endpoint in Phase IIb mesothelioma trial. OncLive (2016). www.onclive.com\/web-exclusives\/tremelimumab-misses-os-endpoint-in-phase-iib-mesothelioma-trial.","journal-title":"OncLive"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-4652(200010)185:1<126::AID-JCP12>3.0.CO;2-2"},{"issue":"15","key":"e_1_3_2_81_1","article-title":"Randomized Phase II study of adjuvant WT1 vaccine (SLS-001) for malignant pleural mesothelioma (MPM) after multimodality therapy. 2016 ASCO Annual Meeting | Abstracts | Meeting Library","volume":"34","author":"Zauderer MG","year":"2016","unstructured":"Zauderer MG , DaoT, RuschVWet al. Randomized Phase II study of adjuvant WT1 vaccine (SLS-001) for malignant pleural mesothelioma (MPM) after multimodality therapy. 2016 ASCO Annual Meeting | Abstracts | Meeting Library. J. Clin. Oncol.34(Suppl. 15), Abstract 8519 (2016).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-5002(00)00192-6"},{"key":"e_1_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.3.1446"},{"key":"e_1_3_2_84_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11357-014-9655-y"},{"key":"e_1_3_2_85_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19941101)74:9<2460::AID-CNCR2820740912>3.0.CO;2-N"},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.121.6.1921"},{"key":"e_1_3_2_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2006.01.007"},{"issue":"8","key":"e_1_3_2_88_1","first-page":"2055","article-title":"Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: an effective in vitro drug sensitization system","volume":"54","author":"Smythe WR","year":"1994","unstructured":"Smythe WR , HwangHC, AminKMet al. Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: an effective in vitro drug sensitization system. Cancer Res.54(8), 2055\u20132059 (1994).","journal-title":"Cancer Res."},{"issue":"10","key":"e_1_3_2_89_1","first-page":"5276","article-title":"Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy","volume":"46","author":"Moolten FL","year":"1986","unstructured":"Moolten FL . Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res.46(10), 5276\u20135281 (1986).","journal-title":"Cancer Res."},{"key":"e_1_3_2_90_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3300385"},{"key":"e_1_3_2_91_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.1996.7.2-141"},{"key":"e_1_3_2_92_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.1998.9.14-2121"},{"key":"e_1_3_2_93_1","doi-asserted-by":"publisher","DOI":"10.1089\/10430349950018904"},{"key":"e_1_3_2_94_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0405"},{"key":"e_1_3_2_95_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1843.2005.00714.x"},{"key":"e_1_3_2_96_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200308000-00001"},{"key":"e_1_3_2_97_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404380"},{"key":"e_1_3_2_98_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0708"},{"key":"e_1_3_2_99_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-010-0871-8"},{"key":"e_1_3_2_100_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.2109"},{"issue":"15","key":"e_1_3_2_101_1","article-title":"CALGB 30601: a Phase II study of dasatinib (D) in patients (pts) with previously treated malignant mesothelioma (MM)","volume":"28","author":"Dudek A","year":"2010","unstructured":"Dudek A , PangH, KratzkeRA, OttersonGA, VokesEE, KindlerHL. CALGB 30601: a Phase II study of dasatinib (D) in patients (pts) with previously treated malignant mesothelioma (MM). J. Clin. Oncol.28(Suppl. 15), Abstract 7037 (2010).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_102_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318248242c"},{"key":"e_1_3_2_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2012.05.111"},{"key":"e_1_3_2_104_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318260dfb9"},{"key":"e_1_3_2_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70056-2"},{"key":"e_1_3_2_106_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318191520c"},{"key":"e_1_3_2_107_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181c5e366"},{"key":"e_1_3_2_108_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2012.02.022"},{"key":"e_1_3_2_109_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000360"},{"key":"e_1_3_2_110_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0996"},{"key":"e_1_3_2_111_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1477"},{"key":"e_1_3_2_112_1","doi-asserted-by":"publisher","DOI":"10.1309\/F1B64CL7H8VJKEAF"},{"issue":"12","key":"e_1_3_2_113_1","first-page":"3862","article-title":"Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE)","volume":"7","author":"Argani P","year":"2001","unstructured":"Argani P , Iacobuzio-DonahueC, RyuBet al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin. Cancer Res.7(12), 3862\u20133868 (2001).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_2_114_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2614"},{"key":"e_1_3_2_115_1","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20110282"},{"key":"e_1_3_2_116_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep01870"},{"key":"e_1_3_2_117_1","first-page":"20","article-title":"Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin","volume":"7","author":"Hassan R","year":"2007","unstructured":"Hassan R , EbelW, RouthierELet al. Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun.7, 20 (2007).","journal-title":"Cancer Immun."},{"key":"e_1_3_2_118_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2275"},{"key":"e_1_3_2_119_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0804"},{"key":"e_1_3_2_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2016.07.003"},{"key":"e_1_3_2_121_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.233"},{"key":"e_1_3_2_122_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.3649"},{"key":"e_1_3_2_123_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-10-461848"},{"key":"e_1_3_2_124_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-0972"},{"key":"e_1_3_2_125_1","doi-asserted-by":"publisher","DOI":"10.5858\/2000-124-1077-MMWCP"},{"key":"e_1_3_2_126_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt832"},{"key":"e_1_3_2_127_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000529"},{"key":"e_1_3_2_128_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-015-0485-1"},{"key":"e_1_3_2_129_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2015.65"},{"key":"e_1_3_2_130_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3947"},{"key":"e_1_3_2_131_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-1008"},{"key":"e_1_3_2_132_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.187"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2017-0224","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:45:00Z","timestamp":1719125100000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2017-0224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":131,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.2217\/fon-2017-0224"],"URL":"https:\/\/doi.org\/10.2217\/fon-2017-0224","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-05-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-06-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-10-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}